National Academy of Sciences | 150 Year Anniversary

Questions? Call 800-624-6242

| Items in cart [0]

The National Academies Press

HARDBACK
price:$52.95
add to cart

Rights & Permissions

topleft topright

Vaccines for the 21st Century: A Tool for Decisionmaking (2000)
Institute of Medicine (IOM)

Citation Manager

. "Overview of Analytic Approach and Results." Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: The National Academies Press, 2000.

Please select a format:

BibTeX EndNote RefMan


Page
81
bottomleft bottomright

The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy.


Vaccines for the 21st Century: A Tool for Decisionmaking

TABLE 4–3 Assumptions and Results of “Vaccine X” Analyses

Vaccine X

Case 1: Mild/Moderate Illness with Deaths, Uniform Ages

Case 2: Mild/Moderate Illness with Deaths, in Children

Case 3: Mild/Moderate Illness with Deaths, in the Elderly

Cases

100,000/yr

100,000/yr

100,000/yr

Age-specific incidence

uniform

all<5

all 65+

Deaths (from acute infection)

1%

1%

1%

Morbidity scenarios

 

Mild scenario

50%

50%

50%

Moderate scenario

50%

50%

50%

Severe scenario

0%

0%

0%

Permanent impairment

0%

0%

0%

Target Population

infants

infants

infants

(infants, adolescents, etc.)

4,000,000

4,000,000

4,000,000

Cost of Vaccine/dose

$50

$50

$50

Discount Rates

 

Health benefits

3%

3%

3%

Costs

3%

3%

3%

a. Immediately available vaccine (100% efficacy and use, no development cost or time)

$/QALY

$89,660

$18,580

$837,629

QALYs to be gained

7,027

25,826

826

Net cost

$630,009,848

$479,838,815

$692,003,742

Cost of care saved

$89,990,152

$240,161,185

$27,996,258

Delivery costs

$720,000,000

$720,000,000

$720,000,000

Development costs

$0

$0

$0

b. Immediately available vaccine with likely effect and use (no development cost or time)

$/QALY

$123,816

$27,873

$1,128,135

Net cost

$587,256,647

$485,891,200

($608,845,879)

Cost of care saved

$60,743,353

$162,108,800

$18,897,474

Delivery costs

$648,000,000

$648,000,000

$648,000,000

Development costs

$0

$0

$0

c. Vaccine available, expected use, and effectiveness with addition of development cost and time

$/QALY

$125,980

$28,462

$1,146,543

QALYs to be gained

3,327

12,227

391

Net cost

$419,089,997

$347,994,312

$448,439,854

Cost of care saved

$42,604,166

$113,699,851

$13,254,308

Delivery costs

$454,494,162

$454,494,162

$454,494,162

Development costs

$7,200,000

$7,200,000

$7,200,000

NOTE: “C” is the primary analysis reported in the results section

Page
81
Front Matter (R1-R12)
Executive Summary (1-10)
Introduction (11-16)
Progress in Vaccine Development (17-38)
Considerations of Candidate Vaccines (39-52)
Overview of Analytic Approach and Results (53-92)
Review of the Analytical Model (93-108)
Ethical Considerations and Caveats (109-122)
Observations (123-132)
References (133-142)
Appendix 1: Borrelia burgdorferi (143-148)
Appendix 2: Chlamydia (149-158)
Appendix 3: Coccidioides Immitis (159-164)
Appendix 4: Cytomegalovirus (165-172)
Appendix 5: Enterotoxigenic E. coli (173-176)
Appendix 6: Epstein-Barr Virus (177-180)
Appendix 7: Helicobacter pylori (181-188)
Appendix 8: Hepatitis C (189-194)
Appendix 9: Herpes Simplex Virus (195-206)
Appendix 10: Histoplasma capsulatum (207-212)
Appendix 11: Human Paillomavirus (213-222)
Appendix 12: Influenza A and B (223-232)
Appendix 13: Insulin-Dependent Diabetes Mellitus (233-238)
Appendix 14: Melanoma (239-244)
Appendix 15: Multiple Sclerosis (245-250)
Appendix 16: Mycobacterium tuberculosis (251-256)
Appendix 17: Neisseria gonnorrhea (257-266)
Appendix 18: Neisseria meningitidis (267-272)
Appendix 19: Parainfluenza Virus (273-278)
Appendix 20: Respiratory Syncytial Virus (279-284)
Appendix 21: Rheumatoid Arthritis (285-290)
Appendix 22: Rotavirus (291-294)
Appendix 23: Shigella (295-298)
Appendix 24: Streptococcus, Group A (299-304)
Appendix 25: Streptococcus, Group B (305-312)
Appendix 26: Streptococcus pneumoniae (313-322)
Appendix 27: Information on accessing Electronic Spreadsheets (323-324)
Appendix 28: Summary of Workshops (325-434)
Appendix 29: Questions Posed to Outside Experts and List of Responders (435-442)
Index (443-460)